Skip to main content

Generic Valtoco Availability

Last updated on Oct 6, 2021.

Valtoco is a brand name of diazepam, approved by the FDA in the following formulation(s):

VALTOCO (diazepam - spray;nasal)

  • Manufacturer: NEURELIS INC
    Approval date: January 10, 2020
    Strength(s): 5MG/SPRAY [RLD], 7.5MG/SPRAY [RLD], 10MG/SPRAY [RLD]

Has a generic version of Valtoco been approved?

No. There is currently no therapeutically equivalent version of Valtoco available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Valtoco. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Absorption enhancers for drug administration
    Patent 10,265,402
    Issued: April 23, 2019
    Assignee(s): Aegis Therapeutics, LLC

    The present invention provides compositions and methods and for increasing the bioavailability of therapeutic agents in a subject. The compositions include at least one alkyl glycoside and at least one therapeutic agent, wherein the alkylglycoside has an alkyl chain length from about 10 to about 16 carbon atoms. In various aspects, the invention provides compositions and methods for oral delivery in the form of a tablet.

    Patent expiration dates:

    • May 11, 2025
      ✓ 
      Drug product
  • Administration of benzodiazepine compositions
    Patent 8,895,546
    Issued: November 25, 2014
    Assignee(s): Hale Biopharma Ventures, LLC

    The invention relates to pharmaceutical compositions comprising one or more benzodiazepine drugs for nasal administration, methods for producing and for using such compositions.

    Patent expiration dates:

    • March 27, 2029
      ✓ 
      Drug product
  • Absorption enhancers for intranasal administration
    Patent 8,927,497
    Issued: January 6, 2015
    Assignee(s): Aegis Therapeutics, LLC.

    A composition including a surfactant and at least one alkyl glycoside and/or saccharide alkyl ester and a drug. The surfactant composition(s) when admixed with a drug is non-toxic and non-irritating, while stabilizing and increasing the bioavailability of the drug. The invention also provides compositions that enhance absorption of drugs via the oral, ocular, nasal, nasolacrimal, inhalation or pulmonary, oral cavity (sublingual or Buccal cell) or CSF delivery route of a patient, including but not limited to insulin, glucagon and exendin-4.

    Patent expiration dates:

    • July 21, 2025
      ✓ 
      Patent use: NASAL ADMINISTRATION OF DIAZEPAM FOR TREATMENT OF INTERMITTENT, STEREOTYPIC EPISODES OF FREQUENT SEIZURE ACTIVITY IN PATIENTS 6 YEARS OF AGE AND OLDER
      ✓ 
      Drug product
  • Pharmaceutical composition including alkyl glycoside and an anti-seizure agent
    Patent 9,642,913
    Issued: May 9, 2017
    Assignee(s): Aegis Therapeutics, LLC.

    A composition including a surfactant and at least one alkyl glycoside and/or saccharide alkyl ester and a drug. The surfactant composition(s) when admixed with a drug is non-toxic and non-irritating, while stabilizing and increasing the bioavailability of the drug. The invention also provides compositions that enhance absorption of drugs via the oral, ocular, nasal, nasolacrimal, inhalation or pulmonary, oral cavity (sublingual or Buccal cell) or CSF delivery route of a patient, including but not limited to insulin, glucagon and exendin-4.

    Patent expiration dates:

    • May 11, 2025
      ✓ 
      Drug product
  • Administration of benzodiazepine compositions
    Patent 9,763,876
    Issued: September 19, 2017
    Assignee(s): Hale Biopharma Ventures, LLC

    The invention relates to pharmaceutical compositions comprising one or more benzodiazepine drugs for nasal administration, methods for producing and for using such compositions.

    Patent expiration dates:

    • March 27, 2029
      ✓ 
      Patent use: NASAL ADMINISTRATION OF DIAZEPAM FOR TREATMENT OF INTERMITTENT, STEREOTYPIC EPISODES OF FREQUENT SEIZURE ACTIVITY IN PATIENTS 6 YEARS OF AGE AND OLDER
      ✓ 
      Drug product

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:

    • January 10, 2023 - NEW PRODUCT
    • January 10, 2027 -

Glossary

Term Definition
Drug Patent A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.